As the industry leader in natural health supplements since 2000, we continually invest in research to provide safe and effective products for joint health.
3 independent clinical studies have scientifically demonstrated that Genacol effectively regenerates collagen in cartilage and significantly reduces joint pain related to osteoarthritis.
We work closely with McGill University to unlock the full benefits or our proprietary ingredient, the AminoLock® Collagen.
Claude has more than 28 years of experience in the pharmaceutical industry, in Europe and Canada, with a solid foundation of university studies in Pharmacy (bachelor), Nutrition, Functional Food, Health (Master) and Regulatory Affairs (Certificate).
Her values are based on Honesty, Transparency and Humanity. Passionate and dedicated, her vision allows the Genacol Research and Development’s Department to create great projects and safe, reliable and effective quality products.
Her goals are to, properly and truly, serve and satisfy the customers by helping them manage their health and wellness needs. She continually seeks to demonstrate new preventive approaches for chronic diseases, in light of recent knowledge and scientific discovery on the role and place of nutraceuticals, functional foods and natural health products in the maintenance of good health.
The Bruyere Study is the first Genacol study that was conducted at the University of Liège in Wallonia, Belgium.
Performed over a six-month period, it included 200 subjects aged at least 50 years old who suffered from joint pain.
Objective: To demonstrate the efficacy of 1200 mg of AminoLock Collagen in relieving joint pain as compared to a placebo.
Results: Subjects who were given AminoLock Collagen instead of a placebo obtained better scores on the VAS, a scale used to measure pain levels. The results demonstrated AminoLock Collagen’s superior efficacy in relieving joint pain.
The PARM Study is the second Genacol study that was conducted at the Veterans Memorial Medical Center in Manila, Philippines.
Performed over a six-month period, it included 113 subjects.
Objective: To demonstrate the efficacy of AminoLock Collagen in relieving knee pain related to osteoarthritis compared to a non-steroidal anti-inflammatory drug.
Results: After 6 months of treatment, subjects who were given the AminoLock Collagen reported a statistically significant reduction in pain, whereas subjects who were given the anti-inflammatory drug reported no significant difference with respect to their pain levels.
The Suarez study is the third Genacol study that was conducted at the University of Santo Tomas Hospital in Manila, Philippines.
The placebo-controlled, triple-blind study included 109 subjects aged at least 50 years old who had experienced knee pain for over a month.
Objective: To determine the efficacy of AminoLock Collagen combined with physical exercise in treating osteoarthritis of the knee.
Results: The study demonstrated that AminoLock Collagen combined with exercise relieves pain, improves general joint function, and encourages interarticular and periarticular structural changes.
ConsumerLab.com, an independent organization that evaluates nutritional products in the USA, recently recognized Genacol’s clinical study as one of the largest studies about hydrolyzed collagen.
The report also mentioned that after 6 months of taking Genacol, the majority of the participants reported a reduction in pain (Bruyere, Comp Ther Med 2012).